Robert More has served as a member of our board of directors since September 2016. Since October 2016, Mr. More has served as Managing Director of Alta Partners, a venture capital firm. From July 2013 to May 2015, Mr. More served as Senior Advisor for the Bill & Melinda Gates Foundation and led its Global Health Venture Initiative. He served as a General Partner of venture capital firms Frazier Healthcare Ventures and Domain Associates from September 2008 to June 2013 and from June 1996 to July 2008, respectively. Mr. More currently serves on the board of directors of Sienna Biopharmaceuticals, Inc., a public pharmaceutical company. He also currently serves on the board of directors of the following private companies: Affinivax, Inc., a biotechnology company, eGenesis, a biotechnology company, Qihan Biotech, a biotechnology company, Sirenas, LLC, a biotechnology company, Tyra Biosciences, Inc., a biotechnology company, and as an advisor on Liquiglide, Inc. a biotechnology company. Mr. More previously served on the board of directors of the following public companies: Achaogen, Inc., a biopharmaceutical company, Carticept Medical, Inc., a medical device company, Cartiva, a medical device company, Neothetics Inc., a pharmaceutical company, Glaukos Corporation, a medical technology company, and IntraLase Corp., a medical device company acquired by Advanced Medical Optics in 2007. He also previously served on the board of directors of the following life sciences companies: ESP Pharma, Inc., Proxima Therapeutics, Inc., NovaCardia, Inc., Esprit Pharma, Inc. and Oceana Therapeutics, Inc. Mr. More was a founding member of the board of directors of the Kauffman Fellows Program and previously served on the board of directors of One Revolution and The Foundation for Innovative New Diagnostics (FIND). Mr. More currently serves on one of the governing boards of the Biotechnology Innovation Organization (BIO). He received his B.S. in Biology from Middlebury College and an M.B.A. from the Darden School of Business Administration at the University of Virginia.
What is Robert J. More's net worth?
The estimated net worth of Robert J. More is at least $570,906.87 as of June 17th, 2021. Mr. More owns 69,369 shares of Vir Biotechnology stock worth more than $570,907 as of April 26th. This net worth evaluation does not reflect any other assets that Mr. More may own. Learn More about Robert J. More's net worth.
How do I contact Robert J. More?
Has Robert J. More been buying or selling shares of Vir Biotechnology?
Robert J. More has not been actively trading shares of Vir Biotechnology during the last ninety days. Most recently, Robert J. More sold 11,670 shares of the business's stock in a transaction on Thursday, July 29th. The shares were sold at an average price of $36.82, for a transaction totalling $429,689.40. Following the completion of the sale, the director now directly owns 47,700 shares of the company's stock, valued at $1,756,314. Learn More on Robert J. More's trading history.
Who are Vir Biotechnology's active insiders?
Vir Biotechnology's insider roster includes Ann Hanly (CTO), Howard Horn (CFO), Robert More (Director), Janet Napolitano (Director), Phillip Pang (Insider), Jay Parrish (Insider), Saira Ramasastry (Director), Steven Rice (Insider), Vicki Sato (Director), George Scangos (CEO), and Herbert Virgin (EVP). Learn More on Vir Biotechnology's active insiders.
Are insiders buying or selling shares of Vir Biotechnology?
In the last twelve months, insiders at the sold shares 26 times. They sold a total of 775,857 shares worth more than $17,733,362.17. The most recent insider tranaction occured on April, 3rd when CEO Backer Marianne De sold 72,995 shares worth more than $690,532.70. Insiders at Vir Biotechnology own 18.1% of the company.
Learn More about insider trades at Vir Biotechnology. Information on this page was last updated on 4/3/2024.
